Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus CHOLINE C 11.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus CHOLINE C 11.
CERETEC vs CHOLINE C-11
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Choline C-11 is a radioactive diagnostic agent; after intravenous administration, it is taken up by cells and phosphorylated by choline kinase. It accumulates in tissues with high choline metabolism, such as tumors (e.g., prostate cancer), allowing positron emission tomography (PET) imaging. The mechanism for tumor uptake is related to increased cell membrane synthesis and choline kinase activity.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
Intravenous: 370-740 MBq (10-20 mCi) as a single injection for PET imaging. Dose depends on patient weight, camera sensitivity, and imaging protocol.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
The terminal elimination half-life of [11C]choline in plasma is approximately 5-10 minutes. This short half-life is consistent with its use as a PET imaging agent, allowing same-day imaging without significant residual radiation exposure.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Primarily renal excretion; approximately 70-80% of administered radioactivity is eliminated in urine within 2 hours, with less than 5% fecal elimination.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical